Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on: December 21,2023 13

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on:December 21,2023 13

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on: October 17,2023 240

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Updated on:October 17,2023 240

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on: July 06,2024 0

Cancer and "Diet Myths": Beware of Pseudoscience in the Social Media Era

Updated on:July 06,2024 0

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on: December 20,2023 25

Multimodal genomic analyses predict response to immunotherapy in lung cancer patients

by Amy Mone,Johns Hopkins University School of MedicineLung cancer. Credit: Jennifer Fairman and Valsamo Anagnostou, Johns Hopkins UniversityResearchers at Johns Hopkins Kimmel Cancer Center, th

Updated on:December 20,2023 25

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on: October 15,2023 284

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on:October 15,2023 284

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on: December 20,2023 15

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on:December 20,2023 15

The chromatographic constitution of andiroba oil and its healing effects

by Impact JournalsHistopathological evaluation of oral mucositis on days 4, 8, 12 and 15. Credit: 2023 Gomes et al.A new research paper titled "The chromatographic constitution of andiroba oil an

Updated on: December 18,2023 15

The chromatographic constitution of andiroba oil and its healing effects

by Impact JournalsHistopathological evaluation of oral mucositis on days 4, 8, 12 and 15. Credit: 2023 Gomes et al.A new research paper titled "The chromatographic constitution of andiroba oil an

Updated on:December 18,2023 15

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023 156

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023 156

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on: December 20,2023 10

Review of American newspapers reveals positive coverage of lung cancer screening

byAmerican Roentgen Ray SocietyKey developments in lung cancer screening are annotated by year. Study period included only first 3 months of 2022, resulting in lower number of articles for that

Updated on:December 20,2023 10

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on: December 22,2023 15

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on:December 22,2023 15

P53 could be key to therapies for salivary gland cancer

Mouse models show that activating a non-mutated form of the gene could lead to developing therapies for salivary gland cancer.Researchers at the University of Michigan Rogel Cancer Center and School o

Updated on: October 31,2023 26

P53 could be key to therapies for salivary gland cancer

Mouse models show that activating a non-mutated form of the gene could lead to developing therapies for salivary gland cancer.Researchers at the University of Michigan Rogel Cancer Center and School o

Updated on:October 31,2023 26

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on: December 22,2023 22

Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives

by NRG OncologyCredit: CC0 Public DomainLung cancer is the leading cause of cancer death in the United States and approximately 75-80 percent of all cases are non-small cell lung cancer (NSCLC). Of th

Updated on:December 22,2023 22